BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Elticertinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Elticertinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06043817-2746@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Elticertinib: Phase 1/2 readout est. (NCT06043817)
DESCRIPTION:Elticertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advan
 ced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 2
 0 Insertion Mutations\nEstimated primary completion: 1 December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/elticertinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06043817
URL:https://assetmemo.bio/drug/elticertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
